PROCEPT BioRobotics (NASDAQ:PRCT) CEO Acquires $498,315.00 in Stock

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) CEO Larry Wood acquired 23,900 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $20.85 per share, with a total value of $498,315.00. Following the completion of the acquisition, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

PROCEPT BioRobotics Stock Down 7.2%

Shares of PROCEPT BioRobotics stock opened at $21.25 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. PROCEPT BioRobotics Corporation has a 1 year low of $16.67 and a 1 year high of $42.71. The firm’s 50-day moving average is $21.29 and its two-hundred day moving average is $24.56. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -10.95 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. During the same quarter in the prior year, the firm posted ($0.35) EPS. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, research analysts expect that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PROCEPT BioRobotics

Institutional investors and hedge funds have recently bought and sold shares of the company. Advisory Services Network LLC grew its stake in PROCEPT BioRobotics by 1.3% during the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after buying an additional 250 shares during the last quarter. Osaic Holdings Inc. raised its stake in PROCEPT BioRobotics by 20.3% in the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after buying an additional 337 shares during the last quarter. ProShare Advisors LLC boosted its holdings in PROCEPT BioRobotics by 4.7% in the fourth quarter. ProShare Advisors LLC now owns 9,726 shares of the company’s stock worth $306,000 after acquiring an additional 438 shares in the last quarter. California State Teachers Retirement System boosted its holdings in PROCEPT BioRobotics by 1.4% in the second quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock worth $2,848,000 after acquiring an additional 693 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after acquiring an additional 746 shares during the last quarter. 89.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on PRCT shares. Wall Street Zen upgraded PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Robert W. Baird set a $20.00 price target on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Truist Financial set a $21.00 price objective on PROCEPT BioRobotics in a research note on Wednesday, August 5th. Jefferies Financial Group reiterated a “hold” rating and issued a $20.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Finally, Evercore set a $23.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, PROCEPT BioRobotics has a consensus rating of “Hold” and an average price target of $28.00.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: CEO Larry Wood purchased 23,900 shares at an average price of $20.85, investing approximately $498,315. The open-market purchase may support investor confidence by signaling that management believes the stock is undervalued. SEC Form 4 filing
• Neutral Sentiment: Several firms reiterated that investors who purchased PRCT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek lead-plaintiff status. These announcements are primarily procedural, but their frequency keeps legal uncertainty in focus. Securities class action deadline notice
• Negative Sentiment: The complaints allege that PROCEPT and certain executives misrepresented demand for its robotic prostate-treatment systems, including repeated underperformance in handpiece sales and procedure activity. The allegations also point to excess customer inventory allegedly created by late-quarter bulk discounts, potentially making reported revenue and growth appear stronger than underlying demand. Hagens Berman class action announcement
• Negative Sentiment: The litigation follows an approximately 18% share-price decline and could increase legal expenses, reputational risk, and scrutiny of PROCEPT’s sales strategy. The concerns are particularly significant because the company remains unprofitable and recently reported a quarterly loss that narrowly exceeded analyst expectations, despite revenue growth. Robbins Geller class action announcement

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.